14个高负担国家常规麻疹疫苗接种和补充免疫活动的健康效果:动态麻疹免疫计算引擎(DynaMICE)建模研究
该建模研究使用年龄结构房室动态模型DynaMICE,评估2000-20年14个高麻疹负担国家不同疫苗接种策略对麻疹易感性和负担的影响。
核心结论
- 包括非选择性补充免疫活动在内的疫苗接种策略比单独MCV2覆盖更大比例未接种儿童并更大幅度降低麻疹负担,但因补充免疫活动目标年龄范围宽而效率较低。
- 该分析为改善麻疹疫苗接种策略的健康效果和效率提供信息,规划未来麻疹疫苗接种策略时应考虑MCV1、MCV2和补充免疫活动之间的相互作用。
研究设计与样本
- 使用年龄结构房室动态模型DynaMICE,评估2000-20年14个高麻疹发病率国家不同疫苗接种策略对麻疹易感性和负担的影响,这些国家包含全球出生队列的53%和全球麻疹负担的78%。
- 从WHO和UNICEF国家免疫覆盖率估计数据库获取所有建模国家1980-2020年国家-specific常规MCV1和MCV2覆盖率数据,从WHO麻疹和风疹补充免疫活动摘要获取补充免疫活动数据。
- 使用预防麻疹病例数和麻疹死亡数估计不同疫苗接种策略的增量健康效果,并使用预防额外一例麻疹所需的增量接种人数(NNV)估计效率。
主要发现
- 尽管增量效果更大,在MCV1基础上加补充免疫活动(中位增量NNV 6.02,5.30-7.68)与加常规MCV2(5.41,4.76-6.11)相比效率降低。
关键数值与推荐
- WHO推荐至少95%人群 coverage 接种两剂含麻疹成分疫苗(MCV)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: WHO recommends at least 95% population coverage with two doses of measles-containing vaccine (MCV). Most countries worldwide use routine services to offer a first dose of measles-containing vaccine (MCV1) and later, a second dose of measles-containing vaccine (MCV2). Many countries worldwide conduct supplementary immunisation activities (SIAs), offering vaccination to all people in a specific age range irrespective of previous vaccination history. We aimed to estimate the relative effects of each dose and delivery route in 14 countries with high measles burden. METHODS: We used an age-structured compartmental dynamic model, the Dynamic Measles Immunization Calculation Engine (DynaMICE), to assess the effects of different vaccination strategies on measles susceptibility and burden during 2000-20 in 14 countries with high measles incidence (containing 53% of the global birth cohort and 78% of the global measles burden). Country-specific routine MCV1 and MCV2 coverage data during 1980-2020 were obtained from the WHO and UNICEF Estimates of National Immunization Coverage database for all modelled countries and SIA data were obtained from the WHO summary of measles and rubella SIAs. We estimated the incremental health effects of different vaccination strategies using prevented cases of measles and deaths from measles and their efficiency using the incremental number needed to vaccinate (NNV) to prevent an additional measles case. FINDINGS: Compared with no vaccination, MCV1 implementation was estimated to have prevented 824 million cases of measles and 9·6 million deaths from measles, with a median NNV of 1·41 (IQR 1·35-1·44). Adding routine MCV2 to MCV1 was estimated to have prevented 108 million cases and 404 270 deaths, whereas adding SIAs to MCV1 was estimated to have prevented 256 million cases and 4·4 million deaths. Despite larger incremental effects, adding SIAs to MCV1 (median incremental NNV 6·02, 5·30-7·68) showed reduced efficiency compared with adding routine MCV2 (5·41, 4·76-6·11). INTERPRETATION: Vaccination strategies, including non-selective SIAs, reach a greater proportion of children who are unvaccinated and reduce measles burden more than MCV2 alone, but efficiency is lower because of the wide age range targeted by SIAs. This analysis provides information to help improve the health effects and efficiency of measles vaccination strategies. The interplay between MCV1, MCV2, and SIAs should be considered when planning future measles vaccination strategies. FUNDING: Gavi, the Vaccine Alliance and the Bill & Melinda Gates Foundation.
引用
- Auzenbergs M, Fu H, Abbas K, et al. Health effects of routine measles vaccination and supplementary immunisation activities in 14 high-burden countries: a Dynamic Measles Immunization Calculation Engine (DynaMICE) modelling study. Lancet Glob Health. 2023. PMID: 37474227. doi:10.1016/S2214-109X(23)00220-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。